Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Okun

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.
Biokhimiia (Moscow, Russia)|July 1, 1989
[Calcium transport in brain synaptosomes during depolarization. The role of potential-dependent channels and Na+/Ca2+ metabolism]S V Konev, S L Aksentsev, I M Okun', et al.
Journal of Combinatorial Chemistry|March 31, 2010
Solution phase parallel synthesis of substituted 3-phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines: selective serotonin 5-HT(6) receptor antagonistsAlexandre V Ivachtchenko, Elena S Golovina, Madina G Kadieva, et al.
Bioorganic & Medicinal Chemistry|June 15, 2010
Synthesis and biological study of 3-(phenylsulfonyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines as potent and selective serotonin 5-HT6 receptor antagonistsAlexandre V Ivachtchenko, Elena S Golovina, Madina G Kadieva, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
Plos One|April 25, 2014
Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffoldsMichael Behr, Johanna K Kaufmann, Patrick Ketzer, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Chest|June 19, 2007
Risk factors for venous thromboembolism after lung transplantationHilary A Yegen, David J Lederer, R Graham Barr, et al.
Journal of Medicinal Chemistry|June 22, 2010
(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptorAlexandre V Ivachtchenko, Dmitri E Dmitriev, Elena S Golovina, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trialBoni E Elewski, Martin M Okun, Kim Papp, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.
Biokhimiia (Moscow, Russia)|July 1, 1989
[Calcium transport in brain synaptosomes during depolarization. The role of potential-dependent channels and Na+/Ca2+ metabolism]S V Konev, S L Aksentsev, I M Okun', et al.
Journal of Combinatorial Chemistry|March 31, 2010
Solution phase parallel synthesis of substituted 3-phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines: selective serotonin 5-HT(6) receptor antagonistsAlexandre V Ivachtchenko, Elena S Golovina, Madina G Kadieva, et al.
Bioorganic & Medicinal Chemistry|June 15, 2010
Synthesis and biological study of 3-(phenylsulfonyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines as potent and selective serotonin 5-HT6 receptor antagonistsAlexandre V Ivachtchenko, Elena S Golovina, Madina G Kadieva, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
Plos One|April 25, 2014
Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffoldsMichael Behr, Johanna K Kaufmann, Patrick Ketzer, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Chest|June 19, 2007
Risk factors for venous thromboembolism after lung transplantationHilary A Yegen, David J Lederer, R Graham Barr, et al.
Journal of Medicinal Chemistry|June 22, 2010
(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptorAlexandre V Ivachtchenko, Dmitri E Dmitriev, Elena S Golovina, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trialBoni E Elewski, Martin M Okun, Kim Papp, et al.
Pageof 11